Department of Radiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
J Neurooncol. 2014 Feb;116(3):543-549. doi: 10.1007/s11060-013-1318-9. Epub 2013 Nov 29.
Abnormal brain tumor vasculature has recently been highlighted by a dynamic susceptibility contrast (DSC) MRI processing technique. The technique uses independent component analysis (ICA) to separate arterial and venous perfusion. The overlap of the two, i.e. arterio-venous overlap or AVOL, preferentially occurs in brain tumors and predicts response to anti-angiogenic therapy. The effects of contrast agent leakage on the AVOL biomarker have yet to be established. DSC was acquired during two separate contrast boluses in ten patients undergoing clinical imaging for brain tumor diagnosis. Three components were modeled with ICA, which included the arterial and venous components. The percentage of each component as well as a third component were determined within contrast enhancing tumor and compared. AVOL within enhancing tumor was also compared between doses. The percentage of enhancing tumor classified as not arterial or venous and instead into a third component with contrast agent leakage apparent in the time-series was significantly greater for the first contrast dose compared to the second. The amount of AVOL detected within enhancing tumor was also significantly greater with the second dose compared to the first. Contrast leakage results in large signal variance classified as a separate component by the ICA algorithm. The use of a second dose mitigates the effect and allows measurement of AVOL within enhancement.
异常的脑肿瘤血管最近被一种动态对比磁共振成像(DSC MRI)处理技术所强调。该技术使用独立成分分析(ICA)来分离动脉和静脉灌注。两者的重叠,即动静脉重叠(AVOL),优先发生在脑肿瘤中,并预测对血管生成抑制剂治疗的反应。对比剂渗漏对 AVOL 生物标志物的影响尚未确定。在 10 名接受脑肿瘤诊断临床成像的患者中,在两次单独的对比剂推注期间采集 DSC。用 ICA 对三个成分进行建模,包括动脉和静脉成分。在增强肿瘤内确定每个成分以及第三个成分的百分比,并进行比较。还比较了增强肿瘤内的 AVOL 在两种剂量之间的差异。对于第一剂对比剂,与第二剂相比,在时间序列中明显有更多的增强肿瘤被归类为具有明显对比剂渗漏的第三个成分,而不是动脉或静脉。与第一剂相比,第二剂检测到的增强肿瘤内的 AVOL 量也明显增加。对比剂渗漏导致信号方差大,被 ICA 算法归类为单独的成分。使用第二剂可以减轻这种影响,并允许在增强区域内测量 AVOL。